Tom Giovanetti is president of the Institute for Policy Innovation (IPI), a 38-year-old conservative, free-market public policy “think tank” based in Dallas, Texas.
In addition to his administrative and fundraising duties, Tom writes for IPI and for leading publications on a variety of policy topics including tax policy, economic growth, self-government, civil liberties and constitutional protections, judicial supremacy, intellectual property, Social Security personal accounts, technology and Internet policy, and government spending. In addition to being regularly published in major outlets including the Wall Street Journal, Washington Times, FoxNews.com and The Dallas Morning News, Tom writes often for the Fort Worth Star-Telegram. Tom frequently appears in the media and is a regular guest and occasional substitute host of the Mark Davis Show in the Dallas-Fort Worth market.
Tom loves thinking out-of-the-box to design novel solutions to policy problems and explaining complicated policy issues in ways average folks can understand.
Tom's mission at IPI is to use issues to teach conservative, free market thinking and to push back against unprincipled populism. He seeks to encourage continued skepticism of Big Government, to maintain faith in markets, and to defend individual liberty as the best means of achieving human flourishing. His most recent work has focused on free market solutions to student loan debt, preserving online freedom, and persuading state legislatures to override local and municipal rules that restrict economic liberty.
Mr. Giovanetti has represented IPI at many national and international organizations, including the World Intellectual Property Organization (WIPO), the Internet Governance Forum (IGF), and represented IPI during negotiations on the Trans-Pacific Partnership (TPP) trade agreement. Mr. Giovanetti is a popular speaker and writer and testifies before state and federal legislative committees on a variety of topics.
Follow Tom on Twitter (X) at @tgiovanetti
IPI Opposes IPI: Problems with a Prescription Drug Pricing Index
IPI urges the Trump administration to forbear importing the price controls of socialist health care systems to the U.S.
Don't Mourn for the Payroll Tax Cut
It’s good news that a payroll tax cut has been dropped from discussion about further Covid-19 economic relief. There are far better ways to provide relief and to attempt economic stimulus.
Coalition Letter Regarding CARES Act Benefit Expiration
While originally intended to provide additional upport for families and businesses complying with government-mandated economic restrictions to address COVID-19, the policy of providing supplemental unemployment insurance has stifled our nation's recovery and is keeping Americans from returning to work.
Relief, Stimulus, and the Right Kind of Stimulus
Any new legislation designed to mitigate the continuing impact of the Covid-19 pandemic should contain both relief and stimulus measures, and full business expensing is an excellent candidate for the stimulus part of the package.
Imagine the Covid-19 Pandemic Without Broadband
While the pandemic has imposed significant costs and losses on the economy, our broadband infrastructure has made it possible to work, shop, learn and be entertained while also maintaining social distancing, and is likely the single biggest factor in reducing the harm to the economy.
Fairness Regulations Chill Free Speech
Under fairness or neutrality regulations for the internet, the most likely result is a chilling effect on internet free speech, under which platforms cannot run the liability risk of allowing political speech on their platforms.
Did the Trump Tax Cuts 'Work'?
As the November election draws nearer, a key issue will be “Did the Trump tax cuts work?” The answer is an unequivocal “yes.”
Attempts to Degrade Drug Patents are Counterproductive in This Pandemic
Compulsory licensing deters innovators from investing in drug discovery. It won’t reduce what patients pay.
Bring American Medical Manufacturing Back Home
Important legislation has been proposed that would encourage medical and pharmaceutical manufacturing to relocate to the U.S. by providing potent tax incentives instead of threats of government force.
Total Records: 737
